Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TASP1 | Q9H6P5 | 1/20 | 0.52 |
| ▸ | ENPEP | Q07075 | 5/20 | 0.47 |
| ▸ | GZMB | P10144 | 2/20 | 0.44 |
| ▸ | CASP1 | P29466 | 1/20 | 0.42 |
| ▸ | CASP3 | P42574 | 1/20 | 0.42 |
| ▸ | CASP4 | P49662 | 1/20 | 0.42 |
| ▸ | CASP5 | P51878 | 1/20 | 0.42 |
| ▸ | CASP9 | P55211 | 1/20 | 0.42 |
| ▸ | CASP6 | P55212 | 1/20 | 0.42 |
| ▸ | CASP8 | Q14790 | 1/20 | 0.42 |
| ▸ | CASP10 | Q92851 | 1/20 | 0.42 |
| ▸ | MAGI3 | Q5TCQ9 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20257131 | 1.00 | TASP1 (0.52) | TASP1ENPEPGZMBCASP1CASP3 | |
| SCHEMBL23132679 | 1.00 | TASP1 (0.52) | TASP1ENPEPGZMBCASP1CASP3 | |
| SCHEMBL23924919 | 1.00 | TASP1 (0.52) | TASP1ENPEPGZMBCASP1CASP3 | |
| SCHEMBL23133165 | 1.00 | TASP1 (0.52) | TASP1ENPEPGZMBCASP1CASP3 | |
| SCHEMBL5746872 | 0.93 | TASP1 (0.61) | TASP1ENPEPGZMBCASP1CASP3 | |
| SCHEMBL20257260 | 0.93 | TASP1 (0.53) | TASP1ENPEPGZMBCASP1CASP3 | |
| SCHEMBL20257263 | 0.93 | TASP1 (0.53) | TASP1ENPEPGZMBCASP1CASP3 | |
| SCHEMBL15485396 | 0.88 | TASP1 (0.49) | TASP1ENPEPGZMB | |
| SCHEMBL23133164 | 0.87 | TASP1 (0.50) | TASP1ENPEPGZMBCASP1CASP3 | |
| SCHEMBL29729257 | 0.87 | ENPEP (0.47) | TASP1ENPEPCASP1CASP3CASP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140056964-A1 | GRANZYME B INHIBITOR COMPOSITIONS, METHODS AND USES FOR PROMOTING WOUND HEALING | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2014-02-27 | — | — | US | claimed |
| US-20230152317-A1 | DIAGNOSIS AND TREATMENT OF COVID-19 | LONDON HEALTH SCIENCES CENTRE RESEARCH INC. (CA) | 2023-05-18 | — | — | US | disclosed |
| WO-2021207858-A1 | DIAGNOSIS AND TREATMENT OF COVID-19 | LONDON HEALTH SCIENCES CENTRE RESEARCH INC. (CA) | 2021-10-21 | — | — | WO | disclosed |
| US-9060960-B2 | Treatment of dissection, aneurysm, and atherosclerosis using granzyme B inhibitors | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2015-06-23 | — | — | US | disclosed |
| US-20140056964-A1 | GRANZYME B INHIBITOR COMPOSITIONS, METHODS AND USES FOR PROMOTING WOUND HEALING | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2014-02-27 | — | — | US | disclosed |
| US-20140056964-A1 | GRANZYME B INHIBITOR COMPOSITIONS, METHODS AND USES FOR PROMOTING WOUND HEALING | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2014-02-27 | — | — | US | disclosed |
| EP-2648735-A2 | GRANZYME B INHIBITOR COMPOSITIONS, METHODS AND USES FOR PROMOTING WOUND HEALING | The University Of British Columbia (CA) | 2013-10-16 | — | — | EP | disclosed |
| WO-2012076985-A2 | GRANZYME B INHIBITOR COMPOSITIONS, METHODS AND USES FOR PROMOTING WOUND HEALING | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2012-06-14 | — | — | WO | disclosed |
| US-20110229546-A1 | TREATMENT OF DISSECTION, ANEURYSM, AND ATHEROSCLEROSIS USING GRANZYME B INHIBITORS | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2011-09-22 | — | — | US | disclosed |
| EP-2205278-A1 | TREATMENT OF DISSECTION, ANEURYSM, AND ATHEROSCLEROSIS USING GRANZYME B INHIBITORS | The University of British Columbia (CA) | 2010-07-14 | — | — | EP | disclosed |
| WO-2009043170-A1 | TREATMENT OF DISSECTION, ANEURYSM, AND ATHEROSCLEROSIS USING GRANZYME B INHIBITORS | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2009-04-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140056964-A1 | GRANZYME B INHIBITOR COMPOSITIONS, METHODS AND USES FOR PROMOTING WOUND HEALING | GZMB, PRF1, SERPINB1 | TASP1 3637/4885ENPEP 319/4885GZMB 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.